why choose us

First received: May 09, 2025

Clinical Trial: The Phase 1, Open-label, PET Trial Designed to Investigate the Effect of AZD2389 on FAP Occupancy in the Liver in Participants With Advanced Liver Fibrosis.

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Liver Fibrosis
Hepatic Cirrhosis

Study Type: INTERVENTIONAL


Official Title: A Phase 1, Open-label Positron Emission Tomography Trial to Assess Changes in Liver Uptake of [68Ga]Ga-FAPI-46 Following Oral Administration of Single Doses of AZD2389 to Patients With Advanced Liver

Brief Summary: This is a phase 1, open-label, PET trial. The study is designed to investigate the effect of AZD2389 on FAP occupancy in the liver in participants with advanced liver fibrosis.

Read more